Personalis, Inc.
PSNL
$8.68
$1.1114.66%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
10/8/2025
-
MarketBeat
10/7/2025
-
Simply Wall St
10/6/2025
-
ETF Channel
10/4/2025
-
Tickeron - Stocks
10/4/2025
-
MarketBeat
10/1/2025
-
Tickeron - Stocks
9/30/2025
-
Tickeron - Stocks
9/30/2025
-
Tickeron - Stocks
Personalis (PSNL, $6.04) entered Uptrend as Momentum indicator ascends above 0 level on Sep 26, 2025
9/27/2025
-
Tickeron - Stocks
Personalis (PSNL, $5.98) entered Downtrend as Momentum indicator drops below 0 level on Sep 25, 2025
9/26/2025
-
Tickeron - Technical Analysis
9/26/2025
-
Tickeron - Technical Analysis
9/25/2025
-
The Fly
9/24/2025
-
Tickeron - Stocks
9/23/2025
-
MarketBeat
9/23/2025
-
Tickeron - Technical Analysis
9/22/2025
-
TipRanks Financial Blog
9/22/2025
-
The Fly
9/20/2025
-
MarketBeat
9/20/2025
-
Tickeron - Stocks
9/20/2025
-
MarketBeat
9/19/2025
-
Tickeron - Stocks
9/18/2025
-
MarketBeat
9/16/2025
-
Simply Wall St
9/15/2025
-
GuruFocus
9/15/2025
-
Business Wire
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, August 5, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
650 752 1300
Address
6600 Dumbarton Circle
Fremont, CA 94555
Fremont, CA 94555
Country
Year Founded
Business Description
Sector
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy...
more